Filing Flows › Ocular Therapeutix (OCUL) › Who owns the stock
Who owns Ocular Therapeutix (OCUL) stock
251 funds reported Ocular Therapeutix (OCUL) shares in their latest 13F filings, worth $2.1B in all. The largest holder is FMR LLC ($323M). Last quarter 126 funds added to their stakes and 106 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| FMR LLC | 32,844,043 | $323M | increase | 2026-06-30 |
| Deep Track Capital, LP | 19,686,282 | $193M | unchanged | 2026-06-30 |
| BlackRock | 19,376,555 | $190M | increase | 2026-06-30 |
| Vanguard Group | 11,575,193 | $141M | increase | 2025-12-31 |
| Avoro Capital Advisors LLC | 12,540,000 | $123M | increase | 2026-06-30 |
| Summer Road LLC | 12,208,296 | $120M | increase | 2026-06-30 |
| VR Adviser, LLC | 10,346,926 | $102M | unchanged | 2026-06-30 |
| Vanguard Capital Management LLC | 8,832,595 | $86.7M | increase | 2026-06-30 |
| Price T Rowe Associates | 7,623,533 | $74.9M | increase | 2026-06-30 |
| Logos Global Management LP | 5,300,000 | $52.0M | increase | 2026-06-30 |
| State Street | 5,233,282 | $51.4M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 5,021,092 | $49.3M | increase | 2026-06-30 |
| Point72 Asset Management, L.P. | 3,292,193 | $32.3M | decrease | 2026-06-30 |
| Dimensional Fund Advisors LP | 2,783,367 | $27.3M | increase | 2026-06-30 |
| Balyasny Asset Management L.P. | 2,270,707 | $22.3M | decrease | 2026-06-30 |
Ocular Therapeutix's latest quarter
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most OCUL stock?
By the latest 13F filings: FMR LLC ($323M); Deep Track Capital, LP ($193M); BlackRock ($190M); Vanguard Group ($141M); Avoro Capital Advisors LLC ($123M).
What is the short interest in OCUL?
28,760,351 shares were sold short at the 2026-10-15 settlement, -2.22% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.